AstraZeneca (LSE:AZN) recently experienced a weekly price move of 2% amid announcements that could have supported its ...

“Baxdrostat BaxHTN Phase III trials on patients with uncontrolled or treatment-resistant hypertension demonstrated a ...

AstraZeneca (AZN) on Monday said that its investigational drug Baxdrostat reduced systolic blood pressure (SBP) compared with ...

AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...

AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a ...

The BaxHTN study met its primary endpoint, and researchers will present more data at the ESC Congress later this summer.

The drug came to AstraZeneca through its acquisition of CinCor Pharma in 2023, with the hopes of beefing up its ...

The readout is particularly welcome for AZ as baxdrostat (formerly CIN-107) showed mixed results in earlier hypertension ...

AstraZeneca's new drug, baxdrostat, has successfully lowered blood pressure in a late-stage trial for treatment-resistant ...

AstraZeneca’s $1.3 billion bet on CinCor Pharma and its mid-phase hypertension drug baxdrostat seems to have paid off based ...

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose hypertension is either uncontrolled by or resistant to existing medicines.

AstraZeneca’s drug candidate baxdrostat lowered systolic blood pressure in a phase 3 clinical trial involving patients with uncontrolled or treatment-resistant hypertension. In the trial, patients who ...